Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for Wegovy to be used for liver treatment. The pharma giant's stock rose more ...

The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...